NCT06392425Not yet recruiting
Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 1 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients 2. Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease 3. Compare serum ADAM 17 and Caspase 3 levels in Diabetic Chronic kidney disease patients and Non Diabetic Chronic kidney disease patients
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 26 Apr 2024
- Start date
- 26 Apr 2024
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Assiut University
- Diseases
- Chronic kidney disease
- NCT number
- NCT06392425
What you commit to
- Study type: Observational
- Planned participants: 90
- From 26 Apr 2024 to the primary completion date, 31 Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with pulmonary oedema or hepatic disease .
- Patients with known any organ malignancy.
Who the study is looking for
- Patients with chronic kidney disease
- Patients with different contributing factors e.g Diabetis mellitus, Hypertension ,autoimmune diseases.
Age in the registry: 18 years to 75 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.